BR0108386C1 - urato oxidase purificada (uricase), conjugado de uricase, composição farmacêutica para reduzir os nìveis de ácido úrico nos fluidos ou tecidos corporais, método para a purificação de uricase dotada de imunogenicidade reduzida - Google Patents

urato oxidase purificada (uricase), conjugado de uricase, composição farmacêutica para reduzir os nìveis de ácido úrico nos fluidos ou tecidos corporais, método para a purificação de uricase dotada de imunogenicidade reduzida

Info

Publication number
BR0108386C1
BR0108386C1 BRC10108386-4A BR0108386A BR0108386C1 BR 0108386 C1 BR0108386 C1 BR 0108386C1 BR 0108386 A BR0108386 A BR 0108386A BR 0108386 C1 BR0108386 C1 BR 0108386C1
Authority
BR
Brazil
Prior art keywords
uricase
conjugate
purification
pharmaceutical composition
uric acid
Prior art date
Application number
BRC10108386-4A
Other languages
English (en)
Other versions
BR0108386B1 (pt
BR0108386A (pt
BRPI0108386B8 (pt
Inventor
David L Williams
Mark G P Saifer
Merry R Sherman
Michael S Hershfield
Susan J Kelly
Original Assignee
Mountain View Pharmaceuticals
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mountain View Pharmaceuticals, Univ Duke filed Critical Mountain View Pharmaceuticals
Publication of BR0108386A publication Critical patent/BR0108386A/pt
Publication of BR0108386C1 publication Critical patent/BR0108386C1/pt
Publication of BR0108386B1 publication Critical patent/BR0108386B1/pt
Publication of BRPI0108386B8 publication Critical patent/BRPI0108386B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

URATO OXIDASE PURIFICADA (URICASE), CONJUGADO DE URICASE,COMPOSIçãO FARMACêUTICA PARA REDUZIR OS NìVEIS DE áCIDO úRICO NOS FLUIDOS OU TECIDOS CORPORAIS, MéTODO PARA A PURIFICAçãO DE URICASE DOTADA DE IMUNOGENICIDADE REDUZIDA A presente invenção se refere a uma proteína de ocorrência natural ou recombinante, em especial a um mutante de urato oxidase de porcino (uricase), que está essencialmente livre de grandes agregados que pode ser tomada substancialmente não imunogênica pela conjugação com um número suficientemente pequeno de filamentos de polímero de modo que a bioatividade da proteína é essencialmente mantida no conjugado. Os referidos conjugados são em geral bem adequados para o tratamento das condições crónicas pelo fato de serem menos propensos a induzir a formação de anticorpos e/ou depuração acelerada do que os conjugados similares preparados a partir das preparações protéicas que contêm traços de grandes agregados.
BRPI0108386A 2000-02-10 2001-02-07 conjugado de uricase, composição farmacêutica e método para a purificação de uricase BRPI0108386B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/501,730 US6783965B1 (en) 2000-02-10 2000-02-10 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PCT/US2001/040069 WO2001059078A2 (en) 2000-02-10 2001-02-07 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Publications (4)

Publication Number Publication Date
BR0108386A BR0108386A (pt) 2002-10-29
BR0108386C1 true BR0108386C1 (pt) 2011-12-20
BR0108386B1 BR0108386B1 (pt) 2017-10-31
BRPI0108386B8 BRPI0108386B8 (pt) 2021-05-25

Family

ID=23994789

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0108386A BRPI0108386B8 (pt) 2000-02-10 2001-02-07 conjugado de uricase, composição farmacêutica e método para a purificação de uricase

Country Status (28)

Country Link
US (3) US6783965B1 (pt)
EP (3) EP2196538B1 (pt)
JP (2) JP5165826B2 (pt)
KR (3) KR101054247B1 (pt)
CN (2) CN100491532C (pt)
AT (1) ATE463576T1 (pt)
AU (3) AU4997501A (pt)
BE (1) BE2013C045I2 (pt)
BR (1) BRPI0108386B8 (pt)
CA (1) CA2398679C (pt)
CY (3) CY1110142T1 (pt)
CZ (1) CZ304864B6 (pt)
DE (1) DE60141742D1 (pt)
DK (3) DK2196538T3 (pt)
ES (2) ES2343105T3 (pt)
FR (1) FR13C0036I2 (pt)
HK (4) HK1056742A1 (pt)
HU (1) HU227127B1 (pt)
IL (3) IL151065A0 (pt)
LU (1) LU92237I2 (pt)
MX (1) MXPA02007545A (pt)
NZ (1) NZ520434A (pt)
PL (1) PL208064B1 (pt)
PT (2) PT1254237E (pt)
RU (3) RU2352354C2 (pt)
TW (2) TW200914617A (pt)
WO (1) WO2001059078A2 (pt)
ZA (1) ZA200207206B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
JP5183836B2 (ja) * 1998-08-06 2013-04-17 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド Ｐｅｇ−尿酸酸化酵素結合体およびその使用
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
PT1100880E (pt) 1998-08-06 2011-01-13 Univ Duke Urato-oxidase
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CA2338665C (en) 1998-08-06 2011-01-18 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
US7229810B2 (en) 2001-06-28 2007-06-12 Mountain View Pharmaceuticals, Inc. Polymer conjugates of proteinases
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP2298278B1 (en) 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
RS20050502A (en) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of interferon- beta with enhanced biological potency
WO2004101600A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel poly(ethylene glycol) modified compounds and uses thereof
ES2395413T3 (es) * 2003-05-12 2013-02-12 Affymax, Inc. Péptidos que se unen al receptor de eritropoyetina
MXPA05012314A (es) * 2003-05-12 2006-04-18 Affymax Inc Radical separador para peptido modificado con polietilenglicol.
CA3050564A1 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
JP2008519858A (ja) * 2004-11-11 2008-06-12 アフィーマックス・インコーポレイテッド エリスロポエチンレセプターに結合する新規ペプチド
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
CA2602654A1 (en) * 2005-04-05 2006-10-12 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Method for shielding functional sites or epitopes on proteins
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
ES2856881T3 (es) 2005-04-11 2021-09-28 Horizon Pharma Rheumatology Llc Formas variantes de urato oxidasa y su uso
EP1871877A2 (en) 2005-04-11 2008-01-02 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
EP1883425A1 (en) * 2005-05-23 2008-02-06 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
ES2532804T3 (es) * 2006-04-12 2015-03-31 Crealta Pharmaceuticals Llc Purificación de proteínas con tensioactivo catiónico
CA2696208A1 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
AU2010265964B2 (en) 2009-06-25 2014-09-18 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
LT2521568T (lt) 2010-01-06 2018-12-10 Dyax Corp. Plazmos kalikreiną surišantys baltymai
US8940861B2 (en) 2010-04-08 2015-01-27 Georgia Tech Research Corporation Variants of ancestral uricases and uses thereof
BR112013017080A8 (pt) 2011-01-06 2023-05-09 Dyax Corp Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
DK3003358T3 (da) 2013-06-07 2021-06-21 Allena Pharmaceuticals Inc Sammensætninger og anordninger til dialyse
CA2917671A1 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US9968595B2 (en) 2014-03-14 2018-05-15 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
EP3294322A4 (en) 2015-05-15 2018-12-12 Medimmune, LLC Improved uricase sequences and methods of treatment
MX2018004587A (es) 2015-10-15 2018-08-14 Agios Pharmaceuticals Inc Terapia de combinacion para tratar tumores malignos.
KR20180067658A (ko) 2015-10-15 2018-06-20 아지오스 파마슈티컬스 아이엔씨. 악성 종양의 치료를 위한 조합물 요법
BR112018011622A2 (pt) 2015-12-11 2018-11-27 Dyax Corp método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
US20230085022A1 (en) 2016-11-11 2023-03-16 Horizon Therapeutics Usa, Inc. Combination therapies of prednisone and uricase molecules and uses thereof
JP2020530282A (ja) 2017-07-07 2020-10-22 アレナ ファーマシューティカルズ， インコーポレイテッド 組換えウリカーゼ酵素
US20190309269A1 (en) 2018-03-20 2019-10-10 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating hyperuricemia and gout
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN109055260B (zh) * 2018-08-08 2021-11-09 淮海工学院 弯曲芽孢杆菌alkaAU及产尿酸氧化酶方法、产品与应用
CN114181917B (zh) * 2022-02-14 2022-06-03 潍坊华卓生物科技有限公司 一种改造尿酸酶、基因序列、制备方法及应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279486C (pt)
US3616231A (en) 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
JPS55135590A (en) 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
CH657141A5 (de) 1980-07-01 1986-08-15 Hoffmann La Roche Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
JPS57192435A (en) 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
DE3126759A1 (de) 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
WO1987000056A1 (en) * 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
DD279486A1 (de) 1986-03-10 1990-06-06 Akad Wissenschaften Ddr Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen
JPS6255079A (ja) * 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
JPH085506B2 (ja) * 1986-08-25 1996-01-24 日東製器株式会社 缶容器
DD279489A1 (de) 1986-12-11 1990-06-06 Leuna Werke Veb Verfahren zur herstellung optisch transparenter epoxidharzformmassen
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5955336A (en) * 1988-08-17 1999-09-21 Toyo Boseki Kabushiki Kaisha DNA sequence for uricase and manufacturing process of uricase
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US5382518A (en) 1989-07-13 1995-01-17 Sanofi Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
JPH03148298A (ja) 1989-11-01 1991-06-25 Sumitomo Pharmaceut Co Ltd 修飾ペプチドおよびその製造方法
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
WO1992016221A1 (en) * 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
DE69233690T2 (de) 1991-07-02 2008-01-24 Nektar Therapeutics, San Carlos Abgabevorrichtung für nebelförmige Medikamente
AU6240494A (en) 1993-02-16 1994-09-14 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
AU6586394A (en) * 1993-04-22 1994-11-08 Celtrix Pharmaceuticals, Inc. Conjugates of growth factor and bone resorption inhibitor
WO1995000162A1 (en) 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
DK0730470T3 (da) * 1993-11-10 2002-06-03 Enzon Inc Forbedrede interferonpolymerkonjugater
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996017929A1 (en) * 1994-12-07 1996-06-13 Novo Nordisk A/S Polypeptide with reduced allergenicity
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
FR2733914B1 (fr) * 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US5853974A (en) 1995-06-07 1998-12-29 Chiron Corporation Enhancement of alkaline phosphatase with SDS in chemiluminescent substrates
JPH09154581A (ja) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
EP1007082B1 (en) 1997-01-15 2006-10-18 Phoenix Pharmacologics, Inc. Modified tumor necrosis factor
EP1500661A1 (en) * 1998-06-01 2005-01-26 Genetech, Inc. Separation of protein monomers from aggregates by use of ion-exchange chromatography
PT1100880E (pt) 1998-08-06 2011-01-13 Univ Duke Urato-oxidase
CA2338665C (en) * 1998-08-06 2011-01-18 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
JP5183836B2 (ja) 1998-08-06 2013-04-17 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド Ｐｅｇ−尿酸酸化酵素結合体およびその使用
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US6425448B1 (en) 2001-01-30 2002-07-30 Cdx Gas, L.L.P. Method and system for accessing subterranean zones from a limited surface area
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
WO2014187953A1 (en) 2013-05-24 2014-11-27 Zentrum Mikroelektronik Dresden Ag Non pwm digital dc-dc converter

Also Published As

Publication number Publication date
KR101054247B1 (ko) 2011-08-08
PT2305819E (pt) 2015-06-01
JP2011188861A (ja) 2011-09-29
HK1056742A1 (en) 2004-02-27
CN1423699A (zh) 2003-06-11
HK1144701A1 (en) 2011-03-04
EP2305819A1 (en) 2011-04-06
JP5341945B2 (ja) 2013-11-13
JP2003521937A (ja) 2003-07-22
HUP0204544A2 (en) 2003-05-28
ES2343105T3 (es) 2010-07-23
HK1143989A1 (en) 2011-01-21
PL358539A1 (en) 2004-08-09
RU2281954C2 (ru) 2006-08-20
DK2305819T3 (en) 2015-01-05
US6783965B1 (en) 2004-08-31
BR0108386B1 (pt) 2017-10-31
EP2196538B1 (en) 2014-10-01
DK1254237T3 (da) 2010-07-19
ATE463576T1 (de) 2010-04-15
US20080057048A1 (en) 2008-03-06
BR0108386A (pt) 2002-10-29
AU2001249975B2 (en) 2006-06-08
CA2398679A1 (en) 2001-08-16
HUP0204544A3 (en) 2007-05-02
RU2352354C2 (ru) 2009-04-20
MXPA02007545A (es) 2002-12-13
JP5165826B2 (ja) 2013-03-21
LU92237I2 (fr) 2013-09-03
FR13C0036I1 (fr) 2013-08-09
EP2196538A1 (en) 2010-06-16
PT1254237E (pt) 2010-06-07
WO2001059078A3 (en) 2002-03-07
RU2557318C9 (ru) 2015-09-10
KR20020087934A (ko) 2002-11-23
RU2557318C2 (ru) 2015-07-20
US20110287466A1 (en) 2011-11-24
BE2013C045I2 (pt) 2020-06-24
CZ304864B6 (cs) 2014-12-17
IL193365A0 (en) 2009-02-11
DK2196538T3 (en) 2015-01-05
CN100491532C (zh) 2009-05-27
HU227127B1 (en) 2010-07-28
CA2398679C (en) 2015-11-17
KR20080098686A (ko) 2008-11-11
AU2009212900A1 (en) 2009-10-01
AU4997501A (en) 2001-08-20
ES2343105T8 (es) 2013-07-15
HK1155203A1 (en) 2012-05-11
AU2009212900B2 (en) 2011-12-08
ZA200207206B (en) 2003-05-06
ES2524153T3 (es) 2014-12-04
DE60141742D1 (de) 2010-05-20
CZ20022982A3 (cs) 2003-01-15
KR100884724B1 (ko) 2009-02-19
CN101735991A (zh) 2010-06-16
CY2013028I2 (el) 2015-11-04
BRPI0108386B8 (pt) 2021-05-25
RU2006107110A (ru) 2007-09-20
PL208064B1 (pl) 2011-03-31
CY1110142T1 (el) 2015-01-14
FR13C0036I2 (fr) 2014-05-16
TW200914617A (en) 2009-04-01
CN101735991B (zh) 2013-09-11
TWI322184B (en) 2010-03-21
US8921064B2 (en) 2014-12-30
US7927852B2 (en) 2011-04-19
KR20070092329A (ko) 2007-09-12
IL151065A (en) 2008-12-29
EP1254237B1 (en) 2010-04-07
IL151065A0 (en) 2003-04-10
EP2305819B1 (en) 2014-11-12
IL193365A (en) 2011-08-31
WO2001059078A2 (en) 2001-08-16
CY2013028I1 (el) 2015-11-04
CY1117264T1 (el) 2017-04-26
NZ520434A (en) 2004-05-28
EP1254237A2 (en) 2002-11-06
RU2009104003A (ru) 2010-08-20

Similar Documents

Publication Publication Date Title
BR0108386C1 (pt) urato oxidase purificada (uricase), conjugado de uricase, composição farmacêutica para reduzir os nìveis de ácido úrico nos fluidos ou tecidos corporais, método para a purificação de uricase dotada de imunogenicidade reduzida
Swann et al. The isolation and partial characterization of the major glycoprotein (LGP-I) from the articular lubricating fraction from bovine synovial fluid
JPH06506248A (ja) 新規な非抗凝固剤ヘパリン誘導体
BR0212999A (pt) novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
CA2107362A1 (en) New non-anticoagulant heparin derivatives
KR920700040A (ko) 내산성 fgf 조성물 및 위장관의 궤양성 질병의 치료방법
Conrad et al. Antibodies against the predominant glycosaminoglycan of the mammalian cornea, keratan sulfate-I.
US20070037756A1 (en) Compositions and methods for the prevention and treatment of circulatory conditions
CN101617053A (zh) 通过添加含二醇的物质调节酶的方法
WO2022095974A1 (zh) 制备聚乙二醇修饰的尿酸氧化酶的方法
US4024247A (en) Composition and method of using a protein mixture derived from liver
WO1994008595A1 (en) Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
WO2001051489A3 (en) Methods for lowering uric acid levels
Hoskins The ABO blood group antigens and their secretion by healthy and diseased gastric mucosa
WO1992017506A1 (en) MODULATION OF tPA ACTIVITY BY HEPARIN FRAGMENTS
CN102964442B (zh) 一种聚乙二醇同神经生长因子结合物的制备方法
EP0767673A4 (en) METHODS FOR REDUCED RENAL ABSORPTION OF ANTIBODY FRAGMENTS
US20150225710A1 (en) Coagulation Factor IX Conjugates
CA1066620A (en) Composition and method of using a protein mixture derived from liver
BRPI0407854A (pt) composição de vacina e método para o tratamento de um paciente que requer um reforço de sua resposta imunológica
JPWO2020205498A5 (pt)

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: A FIM DE ATENDER AO SOLICITADO NA PETICAO DE ESCLARECIMENTO NO 018090054813-SP, DE 10/12/2009, DEVERA O TITULAR APRESENTAR ATRAVES DE FORMULARIO PROPRIO A SOLICITACAO DE TRANSFERENCIA PARCIAL DE TITULARIDADE.

B25A Requested transfer of rights approved

Owner name: MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) , DUKE UN

Free format text: TRANSFERIDO PARTE DOS DIREITOS DE: MOUNTAIN VIEW PHARMACEUTICALS, INC.

B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: A PETICAO DE NO 18120022985-SP, APRESENTADA EM 26/06/2012, EM VIRTUDE DO DISPOSTO NOS ARTS. 218 OU 219 DA LPI (LEI 9279 / 96) DE 14/05/1996, E CONSIDERADA COMO PETICAO NAO CONHECIDA, UMA VEZ QUE O SERVICO REQUERIDO REFERE-SE APENAS AO TITULAR DO DEPOSITO DE PATENTE OU DO PEDIDO DE PATENTE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 9/06 , A61K 47/48 , A61K 38/44

Ipc: A61K 38/44 (2006.01), C12N 9/06 (2006.01), C12N 9/

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: A PETICAO DE NO 18120022984, APRESENTADA EM 26/06/2012, EM VIRTUDE DO DISPOSTO NOS ARTS. 218 OU 219 DA LPI (LEI 9279 / 96) DE 14/05/1996, E CONSIDERADA COMO PETICAO NAO CONHECIDA POR AUSENCIA DE FUNDAMENTACAO LEGAL, UMA VEZ QUE O INPI NAO FAZ ANOTACOES DE ENDERECO DE INVENTOR.

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25B Requested transfer of rights rejected

Owner name: MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) , DUKE UN

B25H Request for change of headquarter rejected

Owner name: MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) , DUKE UN

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: A61K 38/44

Ipc: A61K 47/60 (2017.01), C12N 9/06 (2006.01), C12N 9/

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: A61K 38/44; C12N 9/06; C12N 9/96; A61K 47/48.

Ipc: A61K 47/60 (2017.01), C12N 9/06 (2006.01), C12N 9/

Ipc: A61K 47/60 (2017.01), C12N 9/06 (2006.01), C12N 9/

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: REFERENTE A 20A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/02/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 07/02/2021

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: